Union européenne - anglais - EMA (European Medicines Agency)

eli lilly nederland b.v. - abemaciclib - breast neoplasms - antineoplastic agents - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5.1).in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist.advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.

Union européenne - anglais - EMA (European Medicines Agency)

eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - antineoplastic agents - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment

Union européenne - anglais - EMA (European Medicines Agency)

eli lilly nederland b.v. - pirtobrutinib - lymphoma, mantle-cell - protein kinase inhibitors - treatment of mantle cell lymphoma (mcl)

Irlande - anglais - HPRA (Health Products Regulatory Authority)

eli lilly and company limited - insulin human - suspension for injection - 100 iu/ml - insulin (human)

Irlande - anglais - HPRA (Health Products Regulatory Authority)

eli lilly and company limited - insulin human - suspension for injection - 100 iu/ml - insulins and analogues for injection, intermediate- or long-acting combined with fast-acting

Royaume-Uni - anglais - MHRA (Medicines & Healthcare Products Regulatory Agency)

eli lilly and company ltd - gemcitabine hydrochloride - powder for solution for infusion - 1gram

Royaume-Uni - anglais - MHRA (Medicines & Healthcare Products Regulatory Agency)

eli lilly and company ltd - gemcitabine hydrochloride - powder for solution for infusion - 200mg

Irlande - anglais - HPRA (Health Products Regulatory Authority)

eli lilly and company limited - gemcitabine hydrochloride - pdr for soln for infusion - 1 g grams

Irlande - anglais - HPRA (Health Products Regulatory Authority)

eli lilly and company limited - gemcitabine hydrochloride - pdr for soln for infusion - 200 mg milligram

Israël - anglais - Ministry of Health

eli lilly israel ltd, israel - insulin (human) - solution for injection - insulin (human) 100 iu/ml - insulin (human) - insulin (human) - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis